These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 39006945)
21. VSV based virotherapy in ovarian cancer: the past, the present and …future? Orzechowska BU; Jędryka M; Zwolińska K; Matkowski R J Cancer; 2017; 8(12):2369-2383. PubMed ID: 28819441 [TBL] [Abstract][Full Text] [Related]
22. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer. Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591 [TBL] [Abstract][Full Text] [Related]
23. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614 [TBL] [Abstract][Full Text] [Related]
24. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection. Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567 [TBL] [Abstract][Full Text] [Related]
25. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia. Betancourt D; Ramos JC; Barber GN J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177 [TBL] [Abstract][Full Text] [Related]
26. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Naik S; Nace R; Barber GN; Russell SJ Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623 [TBL] [Abstract][Full Text] [Related]
27. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum. Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134 [TBL] [Abstract][Full Text] [Related]
28. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV. Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874 [TBL] [Abstract][Full Text] [Related]
29. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma. Hastie E; Besmer DM; Shah NR; Murphy AM; Moerdyk-Schauwecker M; Molestina C; Roy LD; Curry JM; Mukherjee P; Grdzelishvili VZ J Virol; 2013 Sep; 87(18):10283-94. PubMed ID: 23864625 [TBL] [Abstract][Full Text] [Related]
30. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919 [TBL] [Abstract][Full Text] [Related]
31. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637 [TBL] [Abstract][Full Text] [Related]
32. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma. Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639 [TBL] [Abstract][Full Text] [Related]
33. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290 [TBL] [Abstract][Full Text] [Related]
34. Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer. Urbiola C; Santer FR; Petersson M; van der Pluijm G; Horninger W; Erlmann P; Wollmann G; Kimpel J; Culig Z; von Laer D Int J Cancer; 2018 Oct; 143(7):1786-1796. PubMed ID: 29696636 [TBL] [Abstract][Full Text] [Related]
35. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853 [TBL] [Abstract][Full Text] [Related]
36. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. Yarde DN; Nace RA; Russell SJ Exp Hematol; 2013 Dec; 41(12):1038-49. PubMed ID: 24067362 [TBL] [Abstract][Full Text] [Related]
37. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. Nelson A; Gebremeskel S; Lichty BD; Johnston B J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474 [TBL] [Abstract][Full Text] [Related]
38. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. Paglino JC; van den Pol AN J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048 [TBL] [Abstract][Full Text] [Related]
39. Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models. Le Boeuf F; Gebremeskel S; McMullen N; He H; Greenshields AL; Hoskin DW; Bell JC; Johnston B; Pan C; Duncan R Mol Ther Oncolytics; 2017 Sep; 6():80-89. PubMed ID: 28856238 [TBL] [Abstract][Full Text] [Related]